Table 2. Comparison of phospho-GluA1-Ser831 and phospho-GluA1-Ser845 levels variation in the middle temporal neocortex, amygdala and head of the hippocampus according to dexamethasone treatment.
| Variables | All cases, n=31, mean (s.e.) | No dexamethasone, n=11, mean (s.e.) | Dexamethasone, n=20, Mean (s.e.) | P-value |
|---|---|---|---|---|
| Middle temporal neocortex | ||||
| P-GluA1-Ser831 | 118.6 (3.2) | 126.9 (6.3) | 114.3 (3.2) | 0.06a |
| P-GluA1-Ser845 | 112.4 (3.0) | 103.1 (4.1) | 117.3 (3.6) | 0.02b |
| Amygdala | ||||
| P-GluA1-Ser831 | 109.3 (3.0) | 122.8 (4.6) | 101.9 (2.8) | 0.0003c |
| P-GluA1-Ser845 | 108.1 (3.3) | 108.2 (6.0) | 108.0 (4.1) | 0.98 |
| Hippocampus | ||||
| P-GluA1-Ser831 | 97.0 (3.7) | 105.2 (7.2) | 92.5 (4.0) | 0.10d |
| P-GluA1-Ser845 | 104.2 (3.6) | 100.5 (7.8) | 106.3 (3.7) | 0.46 |
a
Non-significant trend of 12.6% decrease in the neocortex levels of P-GluA1-Ser831;
b
Non-significant trend of 14.2% decrease in the neocortex levels of P-GluA1-Ser845;
c
Significant decrease of 20.9% in the amygdala levels of P-GluA1-Ser831;
d
Non-significant trend of 12.7% decrease in the hippocampus levels of P-GluA1-Ser831.